Phase II study of hyper-CVAD plus nelarabine in previously untreated T-ALL and lymphoblastic lymphoma.

Trial Profile

Phase II study of hyper-CVAD plus nelarabine in previously untreated T-ALL and lymphoblastic lymphoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2018

At a glance

  • Drugs Nelarabine (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Mercaptopurine; Mesna; Methotrexate; Pegaspargase; Prednisone; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma; T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jan 2018 Results (n=67) assessing safety and efficacy published in the American Journal of Hematology
    • 13 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top